Cyteir Therapeutics, Inc. - Common Stock (NQ:CYT)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cyteir Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

March 07, 2024

From Cyteir Therapeutics

Via Business Wire

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

October 12, 2023

From Cyteir Therapeutics

Via Business Wire

Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher ↗

June 30, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.5% on Friday. The Dow traded up 0.93% to 34,439.75 while the NASDAQ rose 1.54% to 13,800.92. The S&P 500,...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 30, 2023

Via Benzinga

Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851

June 30, 2023

Cyteir Announces Halt of CYT-0851 Development and Company Dissolution Biotech firm Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced today its decision

Via Spotlight Growth

Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 30, 2023

Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...

Via Benzinga

Crude Oil Rises Over 1%; Fed's Preferred Inflation Gauge Slows In May ↗

June 30, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.62% to 34,333.42 while the NASDAQ rose 1.37% to 13,777.52. The S&P 500,...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 30, 2023

Via Benzinga

Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution

June 30, 2023

From Cyteir Therapeutics

Via Business Wire

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

June 03, 2023

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

May 10, 2023

From Cyteir Therapeutics, Inc.

Via Business Wire

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

March 23, 2023

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer

February 06, 2023

From Cyteir Therapeutics

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗

February 03, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway

January 19, 2023

From Cyteir Therapeutics

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023 ↗

January 20, 2023

Via Benzinga

Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights

November 07, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium

October 12, 2022

From Cyteir Therapeutics

Via Business Wire

5 Value Stocks In The Healthcare Sector ↗

September 12, 2022

What are Value Stocks?

Via Benzinga

Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

August 31, 2022

From Cyteir Therapeutics

Via Business Wire

Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights

August 08, 2022

From Cyteir Therapeutics

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

August 01, 2022

From Cyteir Therapeutics

Via Business Wire

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday ↗

July 27, 2022

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

Via Benzinga

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

June 05, 2022

From Cyteir Therapeutics

Via Business Wire

79 Biggest Movers From Yesterday ↗

June 08, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it...

Via Benzinga

Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

May 31, 2022

From Cyteir Therapeutics

Via Business Wire

83 Biggest Movers From Yesterday ↗

May 06, 2022

Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results.

Via Benzinga

Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights

May 05, 2022

From Cyteir Therapeutics

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.